Prognostic significance of IL-17 mRNA expression in peritoneal lavage in gastric cancer patients who underwent curative resection

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 605-612

  Iida, Takeshi ^a   Iwahashi, Makoto ^a   Katsuda, Masahiro ^a   Ishida, Koichiro ^a   Nakamori, Mikihito ^a   Nakamura, Masaki ^a   Naka, Teiji ^a   Ojima, Toshiyasu ^a   Ueda, Kentaro ^a   Hayata, Keiji ^a   Yasuoka, Hironao ^a   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Gastric cancer; Interleukin 17; Peritoneal lavage; Prognostic factor

Indexed keywords

INTERLEUKIN 17; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; GASTRECTOMY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IL 17 GENE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERITONEUM LAVAGE; PERITONEUM METASTASIS; PREDICTION; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL RATE; TUMOR INVASION; TUMOR VOLUME;

AGED; FEMALE; HUMANS; INTERLEUKIN-17; LYMPHATIC METASTASIS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL LAVAGE; PERITONEAL NEOPLASMS; PROGNOSIS; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84892384246     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2911     Document Type: Article

References (31)

1. Takahashi I, Matsusaka T, Onohara T, et al: Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology 47: 1485-1488, 2000.
2. Ito S, Nakanishi H, Kodera Y, Mochizuki Y, Tatemastu M and Yamamura Y: Prospective validation of quantitative CEA mRNA detection in peritoneal washes in gastric carcinoma patients. Br J Cancer 93: 986-992, 2005.
3. Bonenkamp JJ, Songun I, Hermans J and van de Velde CJ: Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg 83: 672-674, 1996.
4. Kodera Y, Nakanishi H, Yamamura Y, et al: Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. Int J Cancer 79: 429-433, 1998.
5. Fujii S, Kitayama J, Kaisaki S, et al: Carcinoembryonic antigen mRNA in abdominal cavity as a useful predictor of peritoneal recurrence of gastric cancer with serosal exposure. J Exp Clin Cancer Res 21: 547-553, 2002.
6. Tokuda K, Natsugoe S, Nakajo A, et al: Clinical significance of CEA-mRNA expression in peritoneal lavage fluid from patients with gastric cancer. Int J Mol Med 11: 79-84, 2003.
7. Boku T, Nakane Y, Minoura T, et al: Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. Br J Surg 77: 436-439, 1990.
8. Kodera Y, Nakanishi H, Ito S, et al: Quantitative detection of disseminated free cancer cells in peritoneal washes with real-time reverse transcriptase-polymerase chain reaction: a sensitive predictor of outcome for patients with gastric carcinoma. Ann Surg 235: 499-506, 2002.
9. Oyama K, Terashima M, Takagane A, Maesawa C, et al: Prognostic significance of peritoneal minimal residual disease in gastric cancer detected by reverse transcription-polymerase chain reaction. Br J Surg 91: 435-443, 2004.
10. Zeimet AG, Widschwendter M, Knabbe C, et al: Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 16: 1861-1868, 1998.
11. Majima T, Ichikura T, Seki S, Takayama E, Hiraide H and Mochizuki H: Interleukin-10 and interferon-gamma levels within the peritoneal cavity of patients with gastric cancer. J Surg Oncol 78: 124-130, 2001.
12. Zhang B, Rong G, Wei H, et al: The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374: 533-537, 2008.
13. Maruyama T, Kono K, Mizukami Y, et al: Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 101: 1947-1954, 2010.
14. + IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 105: 15505-15510, 2008.
15. Langowski JL, Zhang X, Wu L, et al: IL-23 promotes tumour incidence and growth. Nature 442: 461-465, 2006.
16. Kato T, Furumoto H, Ogura T, et al: Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 282: 735-738, 2001.
17. reg skewing. Clin Cancer Res 14: 3254-3261, 2008.
18. Numasaki M, Fukushi J, Ono M, et al: Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620-2627, 2003.
19. Benchetrit F, Ciree A, Vives V, et al: Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99: 2114-2121, 2002.
20. Zou W and Restifo NP: T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10: 248-256, 2010.
21. + Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep 25: 1271-1277, 2011.
22. Kryczek I, Wei S, Zou L, et al: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178: 6730-6733, 2007.
23. Lissoni P, Mandalà M, Curigliano G, et al: Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. Oncology 60: 308-312, 2001.
24. Lenzi R, Rosenblum M, Verschraegen C, et al: Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8: 3686-3695, 2002.
25. Fu QG, Meng FD, Shen XD and Guo RX: Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. World J Gastroenterol 8: 1019-1022, 2002.
26. + T cells in malignant pleural effusion. J Immunol 185: 6348-6354, 2010.
27. + T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 125: 1372-1379, 2009.
28. Kryczek I, Banerjee M, Cheng P, et al: Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149, 2009.
29. Zhang JP, Yan J, Xu J, et al: Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50: 980-989, 2009.
30. Liu J, Duan Y, Cheng X, et al: IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407: 348-354, 2011.
31. + T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology 143: 951.e8-962.e8, 2012.